Literature DB >> 6210279

Different specificities of an HLA-DRw6 haplotype detected by alloreactive T lymphocytes.

L K Myers, E J Ball, P Stastny.   

Abstract

DRw6 has been difficult to define serologically. In the present experiments we have developed T cell lines in order to characterize the components of a DRw6 haplotype. This was accomplished by priming T cells with allogeneic mononuclear cells mismatched for DRw6, Dw6, and MT2. Subsequently, three sublines with distinct reactivity patterns were derived by limiting dilution. The specificities detected by these sublines included: (a) a specificity found on a subset of cells positive for DRw6 which was inhibited by monoclonal antibodies against DS(DC), the human homologue of the murine IA-encoded molecules, (b) another DRw6-associated specificity blocked by an MT2-like antibody, and (c) an MT2-like specificity blocked by monoclonal antibodies reactive with a different MT2-associated determinant. These results show that more than one IE-like, as well as the DS/DC (IA-like) molecules, carry distinctive antigenic epitopes that can be recognized by allogeneic T cells. Primed T cell lines may be useful for a better definition of certain haplotypes which are at present difficult to characterize with serological reagents alone.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6210279     DOI: 10.1016/0198-8859(84)90059-4

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  2 in total

1.  Recognition of class II molecules by human T cells. I. Analysis of epitopes of DR and DQ molecules in a DRw11, DRw52, DQw3 haplotype.

Authors:  L K Myers; E J Ball; G Nuñez; P Stastny
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

2.  Allostimulating cells in man. Quantitative variation in the expression of HLA-DR and HLA-DQ molecules influences T-cell activation.

Authors:  G Nuñez; E J Ball; L K Myers; P Stastny
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.